Pacira BioSciences Current Cash

Pacira BioSciences (PCRX) currently reports a current cash of $250M as of September 2026. That compares with $150M in the prior-year period — up 67.3% year over year. Use the charts on this page to explore Pacira BioSciences's current cash history and peer comparisons.

Pacira BioSciences's current cash increased from $150M to $250M — a 67.3% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacira BioSciences reported $250M in current cash as of September 2026. That compares with $150M in the prior-year period — up 67.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $250M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pacira BioSciences, and consider following PCRX for alerts when major investors trade the stock.

Pacira BioSciences is classified in the Healthcare sector. On current cash, it currently shows $250M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PCRX with unrelated industries.